Skip to Main Content

Good morning, everyone, and welcome to the middle of the week. Congratulations on making it this far and remember, there are only a few more days until the weekend arrives. So keep plugging away. After all, what are the alternatives? While you ponder the possibilities, we invite you to join us for a delightful cup of stimulation. Meanwhile, the time has come to get cracking. So here are a few items of interest. Hope your day goes well. And if you see the Great Pumpkin, please send our regards …

Allergan (AGN) expressed disappointment with early offers from potential buyers for business units it has been trying to sell, and its shares fell more than 7 percent, Reuters writes. The drug maker has been shopping its women’s health and infectious disease businesses since May, following a strategic review of the company undertaken in an effort to reverse a steep slide in its share price. But on a call with analysts to discuss third-quarter results, chief executive officer Brent Saunders said early buyer interest for the units was below the price he believes they are worth.


President Trump may have used the bully pulpit to force Pfizer (PFE) to roll back price hikes last July, but chief executive Ian Read indicated a return to the usual pricing patterns come January, STAT writes. “Well, on pricing, what I’m trying to indicate is that we did voluntarily agree to defer price increases until the (Trump administration) blueprint (on pricing) was implemented over the end of this year,” he says. “We’ve been working with the president on parts of the blueprint. And I expect our approach by the end of year will be, what I would characterize as business as normal.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!